PDF(Sci-hub)
Abstract：
BACKGROUND: We previously studied anti-PD-1 safety in elderly (≥80 years) patients and reported a retrospective two-centre cohort with a similar safety profile in elderly and in younger patients. Quality-of-life evaluation data is still lacking in this specific population.
METHODS: A prospective, single-centre study in patients aged over 75 years presenting metastatic melanoma treated with anti-PD-1. The endpoint was monitoring of quality of life (by a specific survey) and onco-geriatric assessment at the beginning of therapy, then at 3 and 6 months (nutritional status, comorbidities, autonomy, thymic and cognitive disorders).
RESULTS: Fourteen patients were included of median age 86.5 years [range: 78-94] from March to September 2018. General status was good, with a median Charlson score of 0 [extremes 0-4]. Nine patients were evaluated at 3 months and six patients at 6 months. There was no significant difference in quality-of-life scores obtained at baseline, 3 months and 6 months.
CONCLUSIONS: This study shows that neither quality of life nor autonomy appears to be affected by anti-PD-1 treatment in patients aged over 75 years. However, these results should be interpreted with caution due to the small number of patients included, the short follow-up period and the single-centre data. Nevertheless, the prospective analysis and the complete onco-geriatric evaluation and monitoring yielded unique and original data.
METHODS: A prospective, single-centre study in patients aged over 75 years presenting metastatic melanoma treated with anti-PD-1. The endpoint was monitoring of quality of life (by a specific survey) and onco-geriatric assessment at the beginning of therapy, then at 3 and 6 months (nutritional status, comorbidities, autonomy, thymic and cognitive disorders).
RESULTS: Fourteen patients were included of median age 86.5 years [range: 78-94] from March to September 2018. General status was good, with a median Charlson score of 0 [extremes 0-4]. Nine patients were evaluated at 3 months and six patients at 6 months. There was no significant difference in quality-of-life scores obtained at baseline, 3 months and 6 months.
CONCLUSIONS: This study shows that neither quality of life nor autonomy appears to be affected by anti-PD-1 treatment in patients aged over 75 years. However, these results should be interpreted with caution due to the small number of patients included, the short follow-up period and the single-centre data. Nevertheless, the prospective analysis and the complete onco-geriatric evaluation and monitoring yielded unique and original data.
摘要：
背景：我们以前研究了老年（≥80岁）患者的抗PD-1安全性，并报道了一个回顾性的两中心队列，在老年和年轻患者中具有相似的安全性。在这一特定人群中仍然缺乏生活质量评估数据。
方法：前瞻性，单中心研究纳入75岁以上接受抗PD-1治疗的转移性黑色素瘤患者。终点是在治疗开始时监测生活质量（通过特定调查）和老年疾病评估，然后在3个月和6个月(营养状况，合并症,自主性,胸腺和认知障碍)。
结果：从2018年3月至9月，14例患者的中位年龄为86.5岁[范围：78-94]。一般地位很好，Charlson得分为0[极端0-4]。9例患者在3个月时进行评估，6例患者在6个月时进行评估。基线时获得的生活质量评分没有显着差异，3个月和6个月。
结论：这项研究表明，75岁以上患者的生活质量和自主性似乎都不受抗PD-1治疗的影响。然而,由于纳入的患者数量少，这些结果应谨慎解释，短的后续期和单中心数据。然而，前瞻性分析和完整的老年疾病评估和监测产生了独特的原始数据.
方法：前瞻性，单中心研究纳入75岁以上接受抗PD-1治疗的转移性黑色素瘤患者。终点是在治疗开始时监测生活质量（通过特定调查）和老年疾病评估，然后在3个月和6个月(营养状况，合并症,自主性,胸腺和认知障碍)。
结果：从2018年3月至9月，14例患者的中位年龄为86.5岁[范围：78-94]。一般地位很好，Charlson得分为0[极端0-4]。9例患者在3个月时进行评估，6例患者在6个月时进行评估。基线时获得的生活质量评分没有显着差异，3个月和6个月。
结论：这项研究表明，75岁以上患者的生活质量和自主性似乎都不受抗PD-1治疗的影响。然而,由于纳入的患者数量少，这些结果应谨慎解释，短的后续期和单中心数据。然而，前瞻性分析和完整的老年疾病评估和监测产生了独特的原始数据.
